Navigation Links
SPCG-4 trial: Update on watchful waiting versus radical prostatectomy
Date:3/20/2009

Stockholm, 20 March - In 2005, the Scandinavian Prostate Cancer Group Study 4 (SPCG-4) reported that radical prostatectomy improved prostate cancer survival compared with watchful waiting after a median of 8.2 years of follow-up. At the 24th Annual EAU Congress in Stockholm, Sweden the results after 3 more years of follow-up were reported by Professor Lars Holmberg from Uppsala, Sweden.

The SPCG-4 trial which predominantly included men whose prostate cancer was not detected by PSA screening - was the first randomized trial to show that radical prostatectomy reduces the risk of prostate cancer mortality and the risk of developing metastases.

Lars Holmberg: "Key questions following our previous analyses of this trial, which were based on a median of 8.2 years of follow-up, include whether the absolute and relative benefits of surgical treatment would increase during longer follow-up, as we hypothesized; whether overall mortality would remain reduced; whether the benefit is larger among younger than among older patients; and whether histopathologic parameters can predict lethal outcome following surgery. We think the answer may well be affirmative".

The conclusion of the study is that radical prostatectomy reduces prostate cancer mortality and risk of metastases with little or no further increase in benefit 10 or more years after surgery.

Lars Holmberg: "One of the most striking results of this study was the fact that, in a follow-up of side effects, symptoms and quality of life within the randomised study, the symptom profile was different in the two randomisation groups but the overall rating of quality of life was similar. This may mean that the side effects of radical prostatectomy wear off, people get used to it perhaps." This indicates that well structured pre-treatment information, understanding of the patient's preferences and support during follow-up are central to the management of prostate cancer.

"Radical prostatectomy has changed the natural history of prostate cancer. Furthermore it is not sufficient to only to perform PSA tests in post-prostatectomy patients, we do need more tests", says Holmberg.

The SPCG-4 study continues its follow-up. The randomised patients are becoming older men by now which may again result in new and challenging data in the future.


'/>"/>

Contact: lindy brouwer
l.brouwer@uroweb.org
European Association of Urology
Source:Eurekalert

Related medicine news :

1. UNC trial: oral contraceptives may ease suffering of women with severe PMS
2. Pressure BioSciences, Inc. Provides Corporate Update
3. China Pharma Holdings, Inc. Reports Record 2008 Year End Financial Results and Corporate Updates
4. NCCN Presents Updates to NCCN Guidelines for Thyroid Carcinoma
5. Early Detection Remains Key in Updated NCCN Guidelines for Ovarian Cancer
6. New NCCN Guidelines for Primary Cutaneous B-Cell Lymphoma and Updates to NCCN Guidelines for Non-Hodgkins Lymphomas
7. NCCN Announces Updates to Pancreatic Adenocarcinoma Guidelines
8. BullMarket.com Updates Outlook on Biotech Stocks
9. Air Methods Announces Year 2008 Financial Results and Provides First Quarter 2009 Update
10. Alexza Reports 2008 Year-End Financial Results and Updates Clinical Pipeline Status
11. Alexza to Announce 2008 Financial Results and Update Its Clinical Pipeline on Tuesday, March 10, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... , ... On Saturday, October 21, the Health & Wellness Center at Florida ... money for the American Heart Association Heart Walk. Teams of up to 10 people ... keep their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on ...
(Date:10/12/2017)... ... 12, 2017 , ... Vohra Chief Medical Officer Dr. Shark ... skilled nursing facility medical directors and other clinicians at various events in October. ... "At many of these conferences we get to educate other physicians, facility nurses, ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion to ... awards. Ranked as number one in the South Florida Business ... in Inc. 5000 yearly list, the national specialty pharmacy has ... Armando Bardisa will soon be honored by SFBJ as ... Set to receive his award in October, ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/22/2017)... DIEGO , Sept. 22, 2017 AVACEN ... medical device is now successfully helping those with the ... Fibromyalgia diagnosed Amanda in Essex, ... dressed and washing my hair, experiencing no sleep at ... in painful spasm… I cannot recommend [the AVACEN 100] ...
Breaking Medicine Technology: